BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 29990840)

  • 1. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
    Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
    Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Ma L; Fan Z; Du G; Wang H
    Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
    Zhang X; Zhao P; Wang C; Xin B
    Biochem Biophys Res Commun; 2019 Mar; 510(4):508-514. PubMed ID: 30737032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20.
    Yao J; Li Z; Wang X; Xu P; Zhao L; Qian J
    Acta Biochim Biophys Sin (Shanghai); 2016 Feb; 48(2):202-8. PubMed ID: 26758190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.
    Cai B; An Y; Lv N; Chen J; Tu M; Sun J; Wu P; Wei J; Jiang K; Miao Y
    Oncol Rep; 2013 May; 29(5):1769-76. PubMed ID: 23440261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
    Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
    PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
    Fan P; Liu L; Yin Y; Zhao Z; Zhang Y; Amponsah PS; Xiao X; Bauer N; Abukiwan A; Nwaeburu CC; Gladkich J; Gao C; Schemmer P; Gross W; Herr I
    Cancer Lett; 2016 Apr; 373(1):130-137. PubMed ID: 26828016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.
    Sun Y; Wang P; Yang W; Shan Y; Zhang Q; Wu H
    Cancer Biol Ther; 2019; 20(6):729-739. PubMed ID: 30915884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-373-3p enhances the chemosensitivity of gemcitabine through cell cycle pathway by targeting CCND2 in pancreatic carcinoma cells.
    Hu W; Liu Q; Pan J; Sui Z
    Biomed Pharmacother; 2018 Sep; 105():887-898. PubMed ID: 30021382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
    Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
    Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.
    Yang S; He P; Wang J; Schetter A; Tang W; Funamizu N; Yanaga K; Uwagawa T; Satoskar AR; Gaedcke J; Bernhardt M; Ghadimi BM; Gaida MM; Bergmann F; Werner J; Ried T; Hanna N; Alexander HR; Hussain SP
    Cancer Res; 2016 Jul; 76(13):3838-50. PubMed ID: 27197190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-301a transcriptionally activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer.
    Zhang KD; Hu B; Cen G; Yang YH; Chen WW; Guo ZY; Wang XF; Zhao Q; Qiu ZJ
    World J Gastroenterol; 2020 May; 26(19):2349-2373. PubMed ID: 32476798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma.
    Yang F; Li X; Zhang L; Cheng L; Li X
    J Pharmacol Sci; 2018 Jun; 137(2):116-121. PubMed ID: 29960845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
    Zhang L; Yao J; Li W; Zhang C
    Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. microRNA-125a-3p reduces cell proliferation and migration by targeting Fyn.
    Ninio-Many L; Grossman H; Shomron N; Chuderland D; Shalgi R
    J Cell Sci; 2013 Jul; 126(Pt 13):2867-76. PubMed ID: 23606749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer.
    Liu F; Liu B; Qian J; Wu G; Li J; Ma Z
    Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):520-529. PubMed ID: 28459992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal Muscle-Derived Irisin Enhances Gemcitabine Sensitivity and Suppresses Migration Ability in Pancreatic Ductal Adenocarcinoma.
    Sugimoto T; Iwagami Y; Kobayashi S; Yamanaka C; Sasaki K; Yamada D; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
    Ann Surg Oncol; 2024 Jun; 31(6):3718-3736. PubMed ID: 38502294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
    Xie F; Li C; Zhang X; Peng W; Wen T
    Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.